Company profile: Sigyn Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutic technologies for inflammatory diseases, including Sigyn Therapy, a blood purification technology extracting pathogens and inflammatory mediators for endotoxemia, sepsis, and drug-resistant infections; ChemoPrep to enhance chemotherapy delivery by depleting tumor-derived extracellular vesicles; ChemoPure to reduce toxicity by removing off-target agents; and ImmunePrep to boost antibody-based immunotherapies.
Products and services
- ChemoPrep: Medical device that enhances chemotherapy delivery by depleting tumor-derived extracellular vesicles that inhibit chemotherapeutic agents from reaching targets in the bloodstream
- ChemoPure: Medical device that reduces chemotherapy toxicity by removing off-target chemotherapeutic agents from the bloodstream after initial tumor saturation
- Sigyn Therapy: Blood purification technology that extracts pathogens and inflammatory mediators from the bloodstream, targeting endotoxemia, sepsis, and drug-resistant infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sigyn Therapeutics
Viela Bio
HQ: United States
Website
- Description: Provider of clinical-stage treatments for severe inflammation and autoimmune diseases, with a portfolio that selectively targets shared critical pathways at the root cause of disease; led by global leaders in inflammation and autoimmunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viela Bio company profile →
Upstream Bio
HQ: United States
Website
- Description: Provider of antibody therapies targeting the TSLP receptor, developing verekitug (UPB-101), a monoclonal antibody in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and conducting research on Thymic Stromal Lymphopoietin (TSLP) as a driver of inflammatory responses in allergic and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Upstream Bio company profile →
Kadmon
HQ: United States
Website
- Description: Provider of biopharmaceutical products and services for the treatment and management of hepatitis C, including Ribasphere RibaPak (ribavirin, USP) tablets that reduce pill burden and deliver treatment biologically equivalent to other ribavirin medications, and INFERGEN (interferon).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kadmon company profile →
Sudo Biosciences
HQ: United States
Website
- Description: Provider of TYK2 pseudokinase domain–targeting medicines, including a brain-penetrant TYK2 inhibitor for multiple sclerosis and neurodegenerative diseases, and a topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sudo Biosciences company profile →
Blade Therapeutics
HQ: United States
Website
- Description: Provider of discovery-stage drug development focused on oral, small-molecule therapies for fibrotic and neurodegenerative diseases, including cudetaxestat—a Phase 2-ready, non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis; BLD-2184—an IND-ready candidate for neurodegenerative diseases; a class of autotaxin inhibitors; and calpain inhibitors targeting dimeric calpains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blade Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sigyn Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sigyn Therapeutics
2.2 - Growth funds investing in similar companies to Sigyn Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sigyn Therapeutics
4.2 - Public trading comparable groups for Sigyn Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →